Table 5 General linear model of the difference of tdc-gene abundance over time with anti-PD medication and Wexner score as variables in slow and rapid progressing PD patients (significant variable contributions to the model are printed in bold).
Slow progressing PD patients (n = 36) | Rapid progressing PD patients (n = 12) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Difference tdc-gene abundance 2y–0y (no outliers) | Difference tdc-gene abundance 2y–0y (no outliers) | |||||||||||
Not corrected for Wexner score | Corrected for Wexner score | Not corrected for Wexner score | Corrected for Wexner score | |||||||||
β | p value | VIF | β | p value | VIF | β | p value | VIF | β | p value | VIF | |
(Intercept) | 2.1E−06 | 0.001 | 2.4E−06 | 0.000 | 6.5E−07 | 0.589 | 1.3E−06 | 0.511 | ||||
Difference levodopa sum (mg) | 3.4E−09 | 0.436 | 2.120 | 2.7E−09 | 0.506 | 2.133 | 7.1E−10 | 0.868 | 1.879 | −1.2E−09 | 0.848 | 4.149 |
Difference entacapone (mg) | −4.1E−10 | 0.777 | 1.164 | −2.0E−10 | 0.884 | 1.171 | 5.2E–09 | 0.000 | 1.780 | 4.8E−09 | 0.002 | 2.665 |
Difference selegeline (mg) | −1.8E−07 | 0.053 | 1.442 | −1.9E−07 | 0.033 | 1.445 | −2.4E−07 | 0.163 | 3.392 | −2.6E−07 | 0.145 | 3.538 |
Difference rasagiline (mg) | −3.5E−06 | 0.006 | 1.100 | −3.8E−06 | 0.002 | 1.114 | −4.0E–06 | 0.173 | 2.998 | −3.8E−06 | 0.190 | 3.045 |
Difference rotigotine (mg) | 6.1E−07 | 0.038 | 1.287 | 4.5E−07 | 0.117 | 1.388 | 4.8E−07 | 0.072 | 2.494 | 4.3E−07 | 0.141 | 3.033 |
Difference pramipexole (mg) | 2.3E−06 | 0.002 | 1.496 | 2.4E−06 | 0.001 | 1.502 | 1.8E−06 | 0.092 | 2.152 | 7.6E−07 | 0.789 | 14.750 |
Difference ropinirole (mg) | 5.4E−07 | 0.000 | 1.937 | 4.5E−07 | 0.003 | 2.126 | 1.3E−07 | 0.296 | 1.930 | 4.3E−08 | 0.857 | 7.454 |
Difference in Wexner total score | Not included | −2.8E−07 | 0.048 | 1.217 | Not included | −2.7E−07 | 0.680 | 8.843 | ||||
